Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Next Previous
X
Search
Trial Profile

A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Lanifibranor (Primary)
  • Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LEGEND
  • Sponsors Inventiva Pharma

    • Most Recent Events

    • 15 Nov 2024 Results presented in the Inventiva Pharma Media Release.
    • 21 Oct 2024 According to an Inventiva Pharma media release, the results of this study has been accepted as late breaker by the scientific committee of the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 being held November 15 to 19, 2024 in San Diego, California.
    • 09 Jul 2024 Status changed from discontinued to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top